Abstract
Tuberculosis, caused by Mycobacterium tuberculosis, is one of the oldest diseases in the world and is one of the top ten causes of death in the world, ranking first mortality in infectious diseases, far beyond the frightening disease AIDS. Besides that, spinal tuberculosis is the most common form of extrapulmonary tuberculosis, accounting for approximately 1 to 3% of all tuberculosis cases, and accounting for 50% of musculoskeletal infections. However, the drug-resistant situation of spinal tuberculosis is still challenging world wide. This situation directly leads that spinal tuberculosis has a high disability rate and is difficult to treat, which causes a heavy burden to patients, families and society. Therefore, it has been one of the focuses of tuberculosis researchers and spine doctors. Considering that, in this review, we aim to overview the current studies that focused on the novel understanding of current spinal tuberculosis medicine usage and extensive explorations for treating this severe disease.
Keywords: Tuberculosis, spinal, medicine, inflammation, diagnosis, treatment.
Current Medicinal Chemistry
Title:Current Study of Medicinal Chemistry for Treating Spinal Tuberculosis
Volume: 28 Issue: 25
Author(s): Biao Wang, Yuhang Wang and Dingjun Hao*
Affiliation:
- Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an,China
Keywords: Tuberculosis, spinal, medicine, inflammation, diagnosis, treatment.
Abstract: Tuberculosis, caused by Mycobacterium tuberculosis, is one of the oldest diseases in the world and is one of the top ten causes of death in the world, ranking first mortality in infectious diseases, far beyond the frightening disease AIDS. Besides that, spinal tuberculosis is the most common form of extrapulmonary tuberculosis, accounting for approximately 1 to 3% of all tuberculosis cases, and accounting for 50% of musculoskeletal infections. However, the drug-resistant situation of spinal tuberculosis is still challenging world wide. This situation directly leads that spinal tuberculosis has a high disability rate and is difficult to treat, which causes a heavy burden to patients, families and society. Therefore, it has been one of the focuses of tuberculosis researchers and spine doctors. Considering that, in this review, we aim to overview the current studies that focused on the novel understanding of current spinal tuberculosis medicine usage and extensive explorations for treating this severe disease.
Export Options
About this article
Cite this article as:
Wang Biao , Wang Yuhang and Hao Dingjun *, Current Study of Medicinal Chemistry for Treating Spinal Tuberculosis, Current Medicinal Chemistry 2021; 28(25) . https://dx.doi.org/10.2174/0929867328666201222125225
DOI https://dx.doi.org/10.2174/0929867328666201222125225 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Novel Applications of Recombinant Lactic Acid Bacteria in Therapy and in Metabolic Engineering
Recent Patents on Biotechnology Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA
Current Pharmaceutical Design Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Aminoglycoside Antibiotics by Carbohydrate Chemistry
Mini-Reviews in Medicinal Chemistry Novel 2-Nitroimidazole and Imidazooxazole Derivatives and their Activity against <i>Trypanosoma cruzi</i> and <i>Mycobacterium tuberculosis</i>
Medicinal Chemistry Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Metal-N-Heterocyclic Carbene Complexes as Anti-Tumor Agents
Current Medicinal Chemistry Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets Mechanisms at the Interface of Innate and Adaptive Immunity in the Pathogenesis of RSV Disease: Lessons from the Mouse Model
Current Respiratory Medicine Reviews Neglected Diseases Caused By Bacterial Infections
Current Medicinal Chemistry Formulation of Ofloxacin Loaded Lipospheres with Improved Oral Bioavailability
Pharmaceutical Nanotechnology Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Impact of Mast Cell Chymase on Renal Disease Progression
Current Hypertension Reviews An Overview of Currently Available Antimalarials
Current Topics in Medicinal Chemistry Signalling Inhibitors Against Mycobacterium tuberculosis – Early Days of a New Therapeutic Concept in Tuberculosis
Current Medicinal Chemistry Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Many Drugs and Phytochemicals Can Be Activated to Biological Reactive Intermediates
Current Drug Metabolism